Presentation Outline ICHP Annual Meeting September 13-15

Rationale for “Front-Loaded” Approach
• PAH not always a “one drug” disease
• Redundancy of pathways
• Chemotherapeutic or induction approach
AMBITION Trial
A randomized, multicenter study of first-line
AMBrisentan and Tadalafil combination
therapy in subjects with pulmonary arterial
hypertensION
To compare 2 treatment strategies upfront
combo (amb + tad) vs. mono (amb or tad)
Event-driven trial
Primary objective: time to clinical failure
Secondary objectives: safety & tolerability,
6MWD at peak and trough levels
NCT01178073. http://www.clinicaltrials.gov/ct2/show/NCT01178073. Accessed Feb 2012.
REVEAL Registry: Independent Predictors of
Mortality Based on a Multivariate Model
Parameter a Hazard ratio P value
Connective tissue–associated PAH 1.59